clinical trial · NCT05081245
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Autism Spectrum DisorderML-004 (IR)/(ER) tabletML-004 Placebo
brief summary
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
started
Sep 13, 2022
primary completion
Oct 1, 2026
completion
Nov 1, 2026
last updated
Dec 22, 2025
official title
A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol